In heterogeneous catalysis, the catalyst is in a different phase from the reactants. Application In Synthesis of 5-(Bromomethyl)-2,3-dihydro-1,4-benzodioxine, However, they have proven to be challenging because of the mutual inactivation of both catalysts. 214894-89-0, name is 5-(Bromomethyl)-2,3-dihydro-1,4-benzodioxine. In an article,Which mentioned a new discovery about 214894-89-0
ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES
The present invention relates to compound of formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, Formulas (I), (II), (III) and (IV) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent proliferative disorders and their use to manufacture a medicine to treat or prevent proliferative disorders, particularly cancer such as leukemia. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent proliferative disorders. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of proliferative disorders and pathologic conditions such as, but not limited to, cancer such as leukemia.
Note that a catalyst decreases the activation energy for both the forward and the reverse reactions and hence accelerates both the forward and the reverse reactions.Application In Synthesis of 5-(Bromomethyl)-2,3-dihydro-1,4-benzodioxine, you can also check out more blogs about214894-89-0